All In Biotech

Drug Trial Radar · NCT06623162

Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients

Selective Bladder-Sparing Trial with Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients

Last checked: Nov 19, 2026Latest source record: Oct 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Dec 2024

Primary completion

Dec 2026

Study completion Dec 2027

Sponsor

Lead sponsor
Fundación de investigación HMAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
MFAR Clinical Research S.L.; Hospital Universitario 12 de Octubre
First posted
Oct 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Selective Bladder-Sparing Trial with Sasanlimab as Maintenance Treatment Based On Clinical Response To Neoadjuvant Treatment In Molecularly Categorized Muscle Invasive Bladder Cancer Patients

Conditions

  • Mibc
  • Muscle Invasive Bladder Cancer

Interventions

  • gemcitabine + cisplatineDrug

    4 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the bladder-intact overall survival at 12 months after the first dose of sasanlimab. Bladder-intact overall survival is defined as the time from initiation of sasanlimab treatment until death or cystectomyTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hm Sanchinarro

    Madrid, Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.